Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the company’s Board of Directors. Ms. Lyons-Williams brings more than 20 years of executive and operational experience to Pipeline.

“I am thrilled that Lori will be joining the Pipeline board as an independent director,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Lori is an industry leader, and a respected sales and marketing professional. Her experience working on highly successful product launches and pharmaceutical brands will help inform our clinical strategy, as we position Pipeline’s portfolio of neuroregenerative development candidates.”

“I’m excited to be joining Pipeline’s Board of Directors not long after the company’s lead development candidate, PIPE-505, entered the clinic,” said Ms. Lyons-Williams. “I believe Pipeline is uniquely positioned to potentially transform the lives of people living with neurodegenerative conditions, and I look forward to working with Carmine and the team to deliver on our collective mission.”

Ms. Lyons-Williams recently served as the Chief Commercial Officer of Dermira, Inc., prior to its acquisition by Eli Lilly, where she was responsible for developing and implementing the commercial strategy for Dermira’s lead product candidates, including QBREXZA® and lebrikizumab. Previously, she spent 15 years in positions of increasing responsibility at Allergan, with extensive experience in neurotoxins across many indications for BOTOX®. Ms. Lyons-Williams was a member of the Allergan Commercial Leadership Team as well as the Operational Leadership Team.

In addition to her operational experience, Ms. Lyons-Williams is a director of Five Prime Therapeutics (NASDAQ: FPRX), where she serves as a member of the Audit and Compensation Committees.

Ms. Lyons-Williams holds a B.A. in Interdisciplinary Studies with a Pre-Medicine Concentration from Virginia Tech and an M.B.A. from the University of Minnesota’s Carlson School of Management. She is a member of Executive Women in Bio’s Boardroom Ready program, an executive leadership platform helping to diversify life science corporate boards by championing women from the C-suite to the boardroom.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200918005061/en/